Search

e11066 Background: Immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) are reliable ways to identify human epidermal growth factor receptor 2 (HER2) and HER2 amplification. Each technique requires access to tumor tissue and high-quality tissue sample, which may not be available in some patients. HER2 extracellular domain (ECD) may be shed to the serum. The importance of serum ECD in breast cancer (BC) is not yet determined. The first aim of this study was to explore the correlation between serum ECD and HER2 expression in breast cancer tissue. The second aim was to compare ECD levels with clinical and pathological features in early BC patients. Methods: This prospective trial included patients with stage I–III BC. Serum HER2 ECD levels were measured by ADVIA Centaur automated assays before surgical resection of the tumor. Tissue HER2 status was detected by IHC in all tumors. CISH test was utilized in HER2: +2 tumors by IHC. Serum ECD >15ng/ml w...

13569 Background: The combination of 5-FU + LV with irinotecan as first line treatment of advanced colorectal cancer (ACRC) has shown higher response rate compared with 5-FU +LV with the same progression free survival. Capecitabine is more active than 5-FU.The aim of this study is to determine the side-effect profile, dose limiting toxicity and response rate to CapIri combination as first line treatment in ACRC, on an outpatient basis. Methods: Inclusion criteria: age >18–75 years, ECOG ≤ (0–3), measurable disease, no previous treatment for advanced disease, previous adjuvant chemo-therapy more than 6 months is allowed, signed informed consent and adequate hepatic, renal and hematological function. Exclusion criteria: Serious concurrent medical disorders, prior other malignancy, pregnancy or breast-feeding and patients with poor compliance. Capecitabine 1000mg/m2 twice daily was given for 14 days followed by 7 days rest and Irinotecan (100mg/m2) was given days 1 and 8. Treatment was repeated on day 2. Results: 28 patients (pts) were included. All patients were assessable for response and toxicity. Average age was 64 years, male/female ratio 20/8. Fourteen pts had liver metastases, 5 had lung and 9 had abdominal metastases. Median No of cycles was 4. Grade III and IV diarrhea was observed in 12 (44%) pts, vomiting in 9 (31%) pts, fatigue in 12 (44%) pts, grade IV leucopenia in 5 (17%) pts. Complete response was achieved in 3 (11%) pts, partial response in 15 (53%), stabilization of disease in 5 (18%) and tumor progression in 5 (18%) pts. Progression free survival is 8.4 months. Overall survival is not yet available. Conclusions: This regimen appears feasible with acceptable toxicity except for grade III diarrhea, on an outpatient treatment basis, with significant antitumor activity, without the requirement for indwelling catheters. It is also feasible for older patients. No significant financial relationships to disclose.

It has been presented a new technique for measuring thyroxine based on the method first proposed by MurphyPattee 1964. This method was compared to Braverman et al. 1971 technique and to SeligsonSeligson's 1971 one. The advantage of the suggested technique consists in making only one radioactivity measuring in the Sephadex column itself, which avoids the risk of contamination and increase of costs. Therefore, it saves time and permits the automatization of the method by the use of an automatic gamma counter for 200 or 300 tubes.